"Antigens, CD19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
| Descriptor ID |
D018941
|
| MeSH Number(s) |
D23.050.301.264.035.119 D23.050.301.264.051.119 D23.050.301.500.600.200 D23.050.705.552.600.200 D23.101.100.110.119 D23.101.100.150.119
|
| Concept/Terms |
Antigens, CD19- Antigens, CD19
- CD19 Antigens
- B Cell Antigen CD19
- CD19 Antigen
- Antigen, CD19
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD19".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD19 [D23.050.301.264.035.119]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD19 [D23.050.301.264.051.119]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Antigens, CD19 [D23.050.301.500.600.200]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Antigens, CD19 [D23.050.705.552.600.200]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD19 [D23.101.100.110.119]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD19 [D23.101.100.150.119]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD19".
This graph shows the total number of publications written about "Antigens, CD19" by people in this website by year, and whether "Antigens, CD19" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 3 | 4 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 4 | 6 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 4 | 7 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 4 | 5 |
| 2017 | 1 | 2 | 3 |
| 2018 | 3 | 1 | 4 |
| 2019 | 2 | 2 | 4 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 10 | 10 |
| 2023 | 0 | 7 | 7 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, CD19" by people in Profiles.
-
EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy. Blood Adv. 2025 Jan 28; 9(2):270-279.
-
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma. Am J Hematol. 2025 Feb; 100(2):236-248.
-
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Dec 12; 391(23):2219-2230.
-
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354.
-
Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies. Blood Adv. 2024 08 13; 8(15):4066-4076.
-
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024 Oct 20; 42(30):3581-3592.
-
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024 06 27; 143(26):2722-2734.
-
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024 Aug; 30(8):2199-2207.
-
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood Adv. 2024 05 28; 8(10):2327-2331.
-
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol. 2024 Jun 10; 42(17):2071-2079.